摘要
肝细胞癌(HCC)是世界范围内最常见的恶性肿瘤之一,具有起病隐匿、手术切除率低、易早期转移和复发的特点。近年来,随着新的分子生物学技术的发展,一种液体活检技术——循环肿瘤DNA(ctDNA)检测取得了鼓舞人心的成果。本文综述了ctDNA作为HCC患者液体活检的关键成分的研究现状及未来展望,以期为HCC的临床治疗提供新思路。
Hepatocellular carcinoma(HCC)is one of the most common malignant tumors in the world,with the features of insidious onset,low surgical resection rate,and frequent early metastasis and recurrence.With the development of new molecular biology technology in recent years,a liquid biopsy technology,circulating tumor DNA(ctDNA)detection,has achieved encouraging results.This article reviews the current research status and future prospects of ctDNA as a key component of liquid biopsy in patients with HCC,in order to provide new ideas for the clinical treatment of HCC.
作者
侯志远
刘源
杨超然
赵继森
程树杰
HOU Zhiyuan;LIU Yuan;YANG Chaoran;ZHAO Jisen;CHENG Shujie(Department of Hepatobiliary Surgery,Affiliated Hospital of Hebei University,Baoding,Hebei 071000,China)
出处
《临床肝胆病杂志》
CAS
北大核心
2022年第11期2616-2620,共5页
Journal of Clinical Hepatology
基金
河北省自然科学基金(18277790D)。
关键词
癌
肝细胞
肿瘤细胞
循环
DNA
Carcinoma,Hepatocellular
Neoplastic Cells,Circulating
DNA
